These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 6436522)

  • 1. Should donor blood be screened for elevated alanine aminotransferase levels? A cost-effectiveness analysis.
    Silverstein MD; Mulley AG; Dienstag JL
    JAMA; 1984 Nov 23-30; 252(20):2839-45. PubMed ID: 6436522
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum alanine aminotransferase of donors in relation to the risk of non-A,non-B hepatitis in recipients: the transfusion-transmitted viruses study.
    Aach RD; Szmuness W; Mosley JW; Hollinger FB; Kahn RA; Stevens CE; Edwards VM; Werch J
    N Engl J Med; 1981 Apr; 304(17):989-94. PubMed ID: 6782484
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Donor transaminase and recipient hepatitis. Impact on blood transfusion services.
    Alter HJ; Purcell RH; Holland PV; Alling DW; Koziol DE
    JAMA; 1981 Aug; 246(6):630-4. PubMed ID: 6788964
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reducing the incidence of non-A,non-B post-transfusion hepatitis by testing donor blood for alanine aminotransferase: economic considerations.
    Hornbrook MC; Dodd RY; Jacobs P; Friedman LI; Sherman KE
    N Engl J Med; 1982 Nov; 307(21):1315-21. PubMed ID: 6813736
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Declining value of alanine aminotransferase in screening of blood donors to prevent posttransfusion hepatitis B and C virus infection. The Retrovirus Epidemiology Donor Study.
    Busch MP; Korelitz JJ; Kleinman SH; Lee SR; AuBuchon JP; Schreiber GB
    Transfusion; 1995; 35(11):903-10. PubMed ID: 8604486
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of a table-top analyzer for predonation screening for alanine aminotransferase--a cost-effective approach?
    Saxena S; Endahl GL; Shulman IA
    Am J Clin Pathol; 1988 Sep; 90(3):296-9. PubMed ID: 3137804
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alanine aminotransferase and posttransfusion hepatitis.
    Lacher DA
    JAMA; 1987 Feb; 257(8):1048. PubMed ID: 3100827
    [No Abstract]   [Full Text] [Related]  

  • 8. Abnormal alanine aminotransferase level in blood units from donors in Montreal does not indicate high risk of transmitting hepatitis.
    Steinbrecher UP; Kovacs TO; Gelly A; Tourigny M
    Clin Invest Med; 1983; 6(4):327-30. PubMed ID: 6671363
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Based on your analysis of the benefits and costs of routine donor screening for ALT-GPT to reduce the incidence of post-transfusion non-A, non-B hepatitis in your blood services region, what action would you recommend on this matter?
    Vox Sang; 1983; 44(1):48-64. PubMed ID: 6402857
    [No Abstract]   [Full Text] [Related]  

  • 10. Serum alanine aminotransferase (ALT) assay and incidence of posttransfusion non-A,non-B hepatitis.
    Barcena Marugan R; Zamora C; Moreno A; Erdozain Sosa JC; Perez Hernandez F; Lopez San Roman A
    Transfusion; 1989 Oct; 29(8):751. PubMed ID: 2508279
    [No Abstract]   [Full Text] [Related]  

  • 11. Reducing hepatitis by testing blood for alanine aminotransferase.
    Kahn RA
    N Engl J Med; 1983 Apr; 308(14):844-5. PubMed ID: 6403860
    [No Abstract]   [Full Text] [Related]  

  • 12. Correlation of hepatitis C RNA and serum alanine aminotransferase in hepatitis B and C seronegative healthy blood donors.
    Ali N; Moiz B; Moatter T; Ahmed S; Adil SN; Khurshid M
    Indian J Pathol Microbiol; 2010; 53(3):480-5. PubMed ID: 20699507
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nationwide ALT testing to prevent non-A, non-B hepatitis still on hold.
    Cowart VS
    JAMA; 1981 Dec; 246(24):2791-2. PubMed ID: 6796706
    [No Abstract]   [Full Text] [Related]  

  • 14. Alanine aminotransferase levels in Hispanics.
    Carter-Pokras OD; Najjar MF; Billhymer BF; Shulman IA
    Ethn Dis; 1993; 3(2):176-80. PubMed ID: 8324495
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevention of posttransfusion hepatitis B and C by screening for antibody to hepatitis C virus and antibody to HBcAg.
    Chung HT; Lee JS; Lok AS
    Hepatology; 1993 Nov; 18(5):1045-9. PubMed ID: 7693569
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Screening of blood donors for the prevention of non-A, non-B hepatitis].
    Seidl S
    Dtsch Med Wochenschr; 1983 Jan; 108(4):123-4. PubMed ID: 6402351
    [No Abstract]   [Full Text] [Related]  

  • 17. Donor serum alanine aminotransferase activity and the risk of transfusion-associated hepatitis.
    Lenes BA; Tomasulo P; Alter HJ; Holland PV
    N Engl J Med; 1983 Mar; 308(12):723. PubMed ID: 6402702
    [No Abstract]   [Full Text] [Related]  

  • 18. National blood requirement, serum ALT and hepatitis in Ethiopian blood donors.
    Zawde D; Sisay Y
    Ethiop Med J; 1991 Oct; 29(4):175-83. PubMed ID: 1659534
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Occurrence of non-A, non-B post-transfusion hepatitis in heart surgery. Prospective study on the value of the determination of serum alanine aminotransferase and detection of anti-HBc antibodies in blood donors].
    Gayet S; Aymard JP; Janot C; Guillemin C; Briquel ME; Gaucher P; Streiff F
    Rev Fr Transfus Immunohematol; 1986 Dec; 29(6):485-94. PubMed ID: 3108992
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety of the blood supply. Surrogate testing and transmission of hepatitis C in patients after massive transfusion.
    Morris JA; Wilcox TR; Reed GW; Hunter EB; Wallas CH; Steane EA; Shotts SD; Vitsky JL
    Ann Surg; 1994 May; 219(5):517-25; discussion 525-6. PubMed ID: 7514394
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.